Onconetix (ONCO) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for September 5, 2024, to vote on key proposals including director elections, equity plan amendments, a reverse stock split, preferred stock conversions, major share issuances, warrant exercises, auditor ratification, and potential adjournment to solicit more proxies.

• The company recently acquired Proteomedix AG, making it a wholly owned subsidiary, and issued significant equity and preferred stock as consideration, with a total fair value of approximately $65.1 million.

• The company is focusing on commercializing Proclarix, a prostate cancer diagnostic, and has paused commercialization of ENTADFI due to resource constraints and is exploring strategic alternatives for that asset.

• The company faces substantial doubt about its ability to continue as a going concern, with a working capital deficit of $15.1 million and cash sufficient only into Q3 2024, requiring additional capital to sustain operations.

Voting matters and shareholder proposals

• Election of two Class III directors for a three-year term.

• Amendment to the 2022 Equity Incentive Plan to increase available shares by 54,850,000, supporting future grants and the assumption of Proteomedix options.

• Reverse stock split at a ratio between 1-for-30 and 1-for-60 to regain Nasdaq compliance and maintain listing.

• Approval of share issuances upon conversion of Series A and Series B Preferred Stock, including up to 269,672,900 shares for Series B and 5,709,935 for Series A.

• Approval of shares for a $5 million private placement and for the exercise of inducement and placement agent warrants.

• Ratification of EisnerAmper LLP as independent auditor for 2024.

• Authorization to adjourn the meeting if more proxies are needed.

Board of directors and corporate governance

• The board consists of five members, with a mix of Onconetix and Proteomedix designees post-approval.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.

• The board recommends voting “FOR” all proposals.